Three Private Credit Funds Get Moody’s Warning on Problem Loans

Wall Street Reclaims $16 Billion of Deals Lost to Private Credit

Charles River (CRL) Forges Collaboration With Ship of Theseus

Silver Lake Lines Up $8.5 Billion Financing for Endeavor Buyout

Novo Nordisk parent refiles US application on Catalent deal

Novo Nordisk parent refiles US application on Catalent deal

UPDATE 1-Novo Nordisk parent refiles US application on Catalent deal

Ares, Blue Owl Lead $4.8 Billion Private Debt for Catalent Deal

Ozempic, Novo’s $1,000 Diabetes Drug, Can Be Made for Less Than $5 a Month, Study Says

Is Invesco S&P 500 Equal Weight Health Care ETF (RSPH) a Strong ETF Right Now?

Novo Nordisk-owner to expand in India this year

The Top 3 Pharma Stocks to Buy in March 2024

Novo Nordisk hopes to launch experimental obesity drug this decade

HIGHLIGHTS-Novo Nordisk hopes to launch experimental obesity drug this decade

Novo Nordisk will raise capex if Catalent deal is not completed, CFO says

Catalent Publishes Fifth Annual Corporate Responsibility Report, Highlighting Progress and Reinforcing Long-Term Commitment

Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RSPH)?

Novo Nordisk présente de nouveaux traitements de l'obésité et fait le point sur le Wegovy

Novo Nordisk to present early drug trial data, Wegovy supply update

Wegovy Maker Wants Japan to Know It Has an Obesity Problem Too